Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology.
about
Targeting innate immunity for neurodegenerative disorders of the central nervous systemMyalgic Encephalomyelitis: Symptoms and BiomarkersNeuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapyDevelopment of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionAn anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosisThe p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanismQuantitative neuropathological assessment to investigate cerebral multi-morbidity.Generation and behavior characterization of CaMKIIβ knockout mice.Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment.Disease-related microglia heterogeneity in the hippocampus of Alzheimer's disease, dementia with Lewy bodies, and hippocampal sclerosis of aging.Cu(II) enhances the effect of Alzheimer's amyloid-β peptide on microglial activationMW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses.ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing.Persistent activation of microglia and NADPH oxidase [corrected] drive hippocampal dysfunction in experimental multiple sclerosis.The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury.Differential effects of duration and age on the consequences of neuroinflammation in the hippocampusComprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's diseaseClinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brainMechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease.Calcium dysregulation and neuroinflammation: discrete and integrated mechanisms for age-related synaptic dysfunction.Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases.Innate immunity in Alzheimer's disease.Oligodendrocytes and Alzheimer's disease.Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's diseaseRetention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic.Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice.Calcineurin proteolysis in astrocytes: Implications for impaired synaptic functionRepositioning drugs for traumatic brain injury - N-acetyl cysteine and PhenserineAre inflammatory profiles the key to personalized Alzheimer's treatment?Selective inhibition of microglia-mediated neuroinflammation mitigates radiation-induced cognitive impairment.Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease.C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta.Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease.Astaxanthin acts via LRP-1 to inhibit inflammation and reverse lipopolysaccharide-induced M1/M2 polarization of microglial cells.Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice.Neuroinflammation: modulating mighty microglia.Dissecting the pathobiology of altered MRI signal in amyotrophic lateral sclerosis: A post mortem whole brain sampling strategy for the integration of ultra-high-field MRI and quantitative neuropathology.Depression following a traumatic brain injury: uncovering cytokine dysregulation as a pathogenic mechanism
P2860
Q26744219-58B50C91-4F40-4BEA-8B5D-483EF98773F7Q26786545-A04C9CFF-5E1E-4CCE-9181-FEFCC2C63266Q27014919-D83EA089-ED27-4031-86B0-C9744B075568Q27679012-A39736CA-7981-4D95-85FC-49500863907EQ34233438-1368F2DA-B069-4496-ACB9-6AB10DABF306Q34324047-D691BA6D-99E1-4EB8-8DA0-887312B8B7B9Q34584768-24AFD568-9AE5-4082-B93D-6E2BFF6918B3Q35225794-9C449CD3-2734-432D-940A-592FE9E2CE43Q35515670-A7D5364A-D954-485D-BA27-F62E9629D467Q35809944-8B55E10E-7856-46DE-A3BF-F8016061E7ACQ35814412-CB6280D7-0333-4627-9D9B-C999B2696680Q35922026-CFAF175C-B9C7-4339-A0DE-049B473D5214Q36115792-313CCB25-EE57-4C6B-BFEC-A36E20EC2D95Q36591489-013FED0D-EED4-452E-970F-F88A828BB963Q36887359-C3C595AE-8D7E-47ED-B7DC-C0249AC1AA3EQ36997011-8457D314-5672-45E1-8E3E-A43F4A273CCDQ36997908-471CBFC8-7A7C-47A3-8BFE-9C12997B472DQ37532581-E51E2124-0E54-49C8-A3FE-8F79E97AB15BQ38071648-E3C6B724-25B0-4875-B663-D6925B774DADQ38113356-661ECBCC-DF2C-4EB3-9DB8-B23FB58F69C6Q38322767-20F5689F-093F-4957-8DF6-CCD4E622B9BDQ38358574-13355866-8D16-4DEE-AA2B-C80077837489Q38497880-7D7CF65A-781D-4769-AEA4-E66B66A1F327Q38515312-4996A360-1664-4A3D-AB7D-1641607A154CQ38708742-598AD853-E1CB-4C54-A334-745A54ECFBF6Q38910326-D6B297DD-AD96-4810-A09A-72BF30488B40Q39630216-9A9FED61-331D-4542-817F-E99990152D07Q40179990-93302296-8F61-4022-9227-98AA90B0968BQ40741759-7E77463C-400A-4021-A6DE-80E06BBFA59CQ41467872-8170B4FF-C2FB-4A16-9D8A-200C008F373DQ41537684-4B81DDC1-039E-4E2D-A7E8-A24B897B7A93Q41586138-80A79315-FE76-4549-94FE-456018311CDEQ42038294-20A5EC7E-B6ED-4C3F-9132-D32B43791172Q42323104-03A8ACF6-58AF-4E82-8FAC-9A94C6666FBCQ42352469-4858F411-E911-43C3-939F-E3D636B0C035Q42378340-B845DDE3-C05F-4018-BDAF-A3A87C6BFB89Q48292563-2341DF05-14A3-43C3-926A-A47759DE0448Q48457275-9AADF6F8-D6B7-4530-8568-EEA66CCA57AAQ55127801-7C8A6108-1971-4CBC-99C2-2D264300CF73Q58794859-5B404133-44AC-4983-8875-30A1E0CB2A4C
P2860
Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Early stage drug treatment tha ...... r's disease-related pathology.
@en
Early stage drug treatment tha ...... r's disease-related pathology.
@nl
type
label
Early stage drug treatment tha ...... r's disease-related pathology.
@en
Early stage drug treatment tha ...... r's disease-related pathology.
@nl
prefLabel
Early stage drug treatment tha ...... r's disease-related pathology.
@en
Early stage drug treatment tha ...... r's disease-related pathology.
@nl
P2093
P2860
P1476
Early stage drug treatment tha ...... r's disease-related pathology.
@en
P2093
Adam D Bachstetter
Christopher M Norris
D Martin Watterson
Danielle Goulding
Daret St Clair
Donna M Wilcock
Janna H Neltner
Linda J Van Eldik
Pradoldej Sompol
P2860
P304
10201-10210
P356
10.1523/JNEUROSCI.1496-12.2012
P407
P577
2012-07-01T00:00:00Z